Physician profile
Cristina D Meehan
NPI 1598240830
$224,478.24
in general payments reported to CMS, 2019-2025
24 companies · $101K in 2025
The $101K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,578 · 2022: $2,081 · 2023: $39K · 2024: $80K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $109K · Honoraria: $44K · Consulting Fee: $36K · Food and Beverage: $15K · Travel and Lodging: $15K · Education: $11.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $109,062.50 |
| Honoraria | $44,368.00 |
| Consulting Fee | $36,239.00 |
| Food and Beverage | $15,148.01 |
| Travel and Lodging | $14,990.31 |
| Education | $11.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $114,444.52 | 2021-2025 | |
| Axsome Therapeutics, INC. | $91,441.17 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $10,900.68 | 2023-2024 | Loreev Xr |
| Corium, LLC | $2,105.94 | 2022-2025 | Azstarys, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,457.17 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $907.09 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $526.14 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $381.37 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $348.64 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $328.62 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $302.56 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $286.78 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $286.50 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $264.98 | 2021-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $118.86 | 2023-2024 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $112.63 | 2021 | |
| Collegium Pharmaceutical, INC. | $71.80 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $41.66 | 2022 | |
| Tris Pharma INC | $37.79 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $35.67 | 2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $22.77 | 2023 | Invega Sustenna |
| Tempus Ai, INC | $22.50 | 2024 | |
| Vertical Pharmaceuticals, LLC | $17.03 | 2024 | Relexxii |
| Neuronetics, INC. | $15.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristina Meehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.